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Debate: Do all patients with heart failure require automatic
implantable defibrillators for the prevention of sudden death?
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Abstract
Recent clinical trials indicate that approximately two-thirds of patients in New York Heart
Association (NYHA) class II and III, who comprise almost 90% of patients with heart failure,
die suddenly. Patients in NYHA class IV usually die of progressive heart failure. Implantation
of implantable cardioverters defibrillators (ICDs) in this population would represent a huge
logistic problem and economic expense. Clinical trials have recently demonstrated that b-
blocker therapy with carvedilol, bisoprolol, and toprol XL decrease the sudden death rate by
almost 50%, in addition to impacting significantly on death due to worsening heart failure.
This medical approach is beneficial to all patients, and should be our major therapy.
However, it is reasonable to attempt to identify that subpopulations of heart failure patients
who could benefit from an ICD.
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Sudden death has been recognized as an important public
health problem for over four centuries. In the 18th century,
Pope Clement XI became concerned with the increase in
occurrence of sudden death in Rome, and charged his
papal physician Geofredo Lancisi to investigate its cause to
no avail. Through the centuries the instantaneous nature of
death has provided both a scientific and spiritual challenge
to investigators to understand its mechanism. Despite the
interest and intense investigation, neither Lancisi nor subse-
quent investigators have advanced our understanding of
either the physiologic triggers of the event, or the nature of
the event itself. There have been numerous electrocardio-
graphic recordings of the event, but they have provided little
insight into its mechanism. Cardiac arrest is largely
expressed as ventricular fibrillation, but in approximately
20% of patients the event is due to asystole.
With the development of emergency medical care
systems, relatively large populations of resuscitated
cardiac arrest became available for both retrospective and
prospective study. These studies indicate that cardiac
arrest usually occurs in individuals who are known to have
cardiovascular disease and who have left ventricular dys-
function [1]. Although sudden death can occur as the first
expression of coronary heart disease, and usually as an
acute myocardial infarction, even in these individuals priorCurrent Controlled Trials in Cardiovascular Medicine    Vol 1 No 2 Goldstein
evidence of left ventricular damage or dysfunction is
present. In addition, many individuals with nonischemic left
ventricular dysfunction also experience sudden cardiac
arrest. Investigators have used animal models and single-
cell preparations in an attempt to understand the mecha-
nism of ventricular fibrillation in order to prevent its
occurrence. All of these attempts have been frustrated by
the instantaneous and transient nature of the physiologic
phenomena that precipitate cardiac arrest.
For a large part of the past half century, a great deal of
research was focused on the suppression of ambient ven-
tricular beats as a surrogate marker of the efficacy of antiar-
rhythmic drugs. The number of pharmacologic blind alleys
that were entered are too numerous to recount, but it is
clear that no agent directed at the suppression of ventricular
premature beats has been found to be either safe or effec-
tive. The most recent investigations with amiodarone carried
out in Europe [2] and Canada [3] failed to demonstrate any
convincing evidence for its use for the prevention of sudden
death, although the concomitant use of b-blockers with
amiodarone appeared to offer some advantage.
With unusual prescience and technologic skill, Mirowski
realized that antiarrhythmic therapy was a blind alley and
began the development of the automatic internal defibrilla-
tor almost 40 years ago, and reported its first successful
use in humans in 1980 [4]. That device is refined to such a
degree that it is now easily implantable; it is small in size,
but still large in cost. Its proven efficacy has spawned a
large industry of both physicians and biotech companies
that are directed at the expanded clinical use of the device.
Although the American Heart Association and the Ameri-
can College of Cardiology have reported implantation
guidelines [5], common clinical practice has led to a sig-
nificant deviation from those guidelines. The ease of
implantation and the fear of recurrent sudden death have
encouraged both the patient and physician to ‘creep-up’
on the guidelines. There is little argument that implantation
of the ICD in patients with recurrent ventricular fibrillation
or symptomatic ventricular tachyarrhythmias in the
absence of acute myocardial infarction or ischemia is ben-
eficial [6]. Even in this regard, however, the definition has
been vague and has provided a window through which
any syncopal episode, with little more than the presence
of complex ventricular ectopy, has become fair game for
the implantation of the ICD in patients with left ventricular
dysfunction. Many of the patients who receive an ICD
would have been better been treated with revasculariza-
tion or b-blocker therapy. It is essential to understand this
practice reality as we embark on the following discussion.
Recently, patients with heart failure have become a poten-
tial target population for implantation of an ICD. It is esti-
mated that there are almost 5 million individuals with heart
failure in the USA. Initially, the device was considered as a
bridge to transplantation, because the mortality rate, often
sudden death, in patients waiting for a donor heart was
high. It soon became clear, however, that most of the
patients who were dying on the transplant waiting list
were dying of rhythm disturbances as a complication of
worsening heart failure [7]. In these patients, use of an
ICD had little benefit. As electrophysiologists became
aware of the natural history of heart failure, they realized
that sudden death was actually a greater problem in
patients with NYHA class II and III than in those with
advanced heart failure. Recent clinical trials have empha-
sized that sudden death represents almost two-thirds of
the mortality in mild-to-moderate heart failure [8]. Heart
failure therapy for most of the past decade has been
based primarily on angiotensin-converting enzyme (ACE)
inhibitors, which had little effect on arrhythmic death.
The striking decrease in sudden death in the recent b-
blocker trials [8–10] has provided, for the first time, a
pharmacologic approach to sudden death. These observa-
tions could have been assumed from studies in post-
myocardial infarction patients with congestive heart failure
[11], in whom propanolol was shown to have a profound
effect on sudden death. The recent trials have demon-
strated an decrease in total mortality in addition to a
decrease in sudden death by 40–50%, without any
adverse effects and excellent tolerance. Therapy with b-
blockers has provided an entirely new approach to both
the treatment of heart failure and the prevention of sudden
death. The reduction in sudden death mortality was
observed across a broad spectrum of subgroups studied
in the Metoprolol CR/XL Randomized Intervention Trial in
Congestive Heart Failure (MERIT-HF) [8], the largest b-
blocker mortality trial, regardless of ejection fraction or
heart failure etiology. Not only do these drugs decrease
the incidence of sudden death, but they also have an
important effect on total cardiovascular mortality and
death due to worsening heart failure [8]. Treatment with
carvedilol, bisoprolol and metoprolol in the three major
randomized clinical trials [8–10] decreased the total mor-
tality by approximately 35% and sudden death by 45%.
More recently, patients in NYHA class III–IV who were
treated with spironolactone experienced a 29% decrease
in incidence of sudden death, in addition to a 31%
decrease in cardiovascular deaths [12]. It is possible that
a combination of these drugs could make an even larger
impact on sudden death prevention.
The annual cardiovascular mortality rate in patients with
heart failure treated with ACE inhibitors and b-blockers is
now approximately 7% in NYHA class II and III patients.
Although sudden death remains an important problem, to
which a device could appropriately be applied, this solu-
tion would pertain to less than 5% of the heart failure
patients treated with b-blockers. It can be estimated that,c
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if the ICD was implanted in 100 patients treated with ACE
inhibitors and b-blockers, sudden death could be pre-
vented in five individuals over the next year. This is pre-
suming that the AID would prevent all of the deaths due to
ventricular fibrillation or asystole and that none of the
sudden deaths were due to acute progression of the
primary disease. Because many of these individuals have
ischemic heart disease, it can be presumed that some will
experience further loss of ventricular function as a result of
myocardial infarction. Asystole is also assumed to be suc-
cessfully treated by the ICD, because most of the devices
have pacing capability.
The estimated benefit that could be achieved by ICD is
rather small and would be obtained at a considerable cost.
This cost is significant in the face of the almost 5 million
individuals in the USA with heart failure. Little has been
said about the risk or side effects of the device when left
in place for years or the discomfort of inappropriate dis-
charge. It is clear, however, that ICD implantation and its
safety have improved during the past few years.
The device that Mirowski [4] developed over 40 years ago
has moved far beyond his vision at that time. The appropri-
ate role for the ICD is still being explored. A number of
major trials [13,14] are now underway to examine the
benefit of these devices in heart failure patients. Although
these trials fall short in their design, because they do not
mandate b-blocker therapy, they will expand our under-
standing of the usefulness of ICD in heart failure. Perhaps a
more appropriate research direction would be to try to iden-
tify those persons within the large population of heart failure
patients who would benefit the most from implantation of an
ICD. Unfortunately, the easiest answer to the question of
who should have the device implanted is to implant it into
everyone. This appears to be the most expedient if not effi-
cient approach to the problem, and the one that appears to
hold sway in today’s clinical practice. I would submit that
the benefit of the ICD must be judged in terms of both the
socioeconomic and medical costs. In the interval period, it is
clear that the addition of b-blocker therapy to the treatment
of the broad spectrum of patients with heart failure has pro-
vided important protection from sudden death and death
due to progressive heart failure. It is my view that the ICD
will add little additional benefit to the treatment of patients
with mild-to-moderate heart failure.
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